ASSURE study of experimental agent to improve HDL yields ‘disappointing and astonishing’ results The search continues for an agent that increases high-density lipoprotein and reduces arterial plaque, following the experimental apolipoprotein A1 inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation study. The lack of efficacy of RVX-208 is ‘disappointing and unexpected, given promising earlier results,’ noted business lead investigator Stephen Nicholls MBBS, PhD, Deputy Director at the South Australian Health and Medical Research Institute, Professor of Cardiology at the University of Consultant and Adelaide Cardiologist at the Royal Adelaide Medical center in Adelaide, Australia.Furthermore, this database will be available online by the scientific community and can represent an invaluable tool for future research projects. This database will link state-of-the-art genetic analysis to very detailed behavioral assessments. That is an unprecedented project that could enhance our understanding of underlying biological procedures greatly, explains Dr. Fombonne. That is an important step towards the unraveling of genetic mechanisms and understanding the pathophysiology of this disorder of brain advancement. Families are being recruited to take part in an initial evaluation and then could be invited to take part in other research projects as function continues. Those permitted participate are families with only one kid with an autism spectrum disorder who is four years of age or older; with a number of siblings without an ASD, age group four or old; and biological parents without an ASD and who are willing to participate.